Aurobindo Pharma Share Price

Aurobindo Pharma

CMP as on 27-Oct-21 15:51

₹ 706.60
3.10 0.44%

Open

₹ 704.70

Turnover (lac)

₹ 11,570

Prev. Close

₹ 703.50

Day's Vol (shares)

₹ 16,37,432

Day's Range (₹)

₹ 702.55
₹ 714.75

CMP as on27-Oct-21 15:53

₹ 706.10
2.3 0.33%

Open

₹ 701.00

Turnover (lac)

₹ 766

Prev. Close

₹ 703.80

Day's Vol (shares)

₹ 1,07,404

Day's Range

₹ 701.00
₹ 714.40

CMP as on 27-Oct-21 15:29

₹ 704.70
1.05 0.15%

Open

₹ 704.00

Open Interest(Contracts)

₹ 79,68,350

VWAP

₹ 709.72

Day's Vol (shares)

₹ 51,14,200

Day's Range (Ex.Dt. 28 Oct 2021)

₹ 703.60
₹ 716.25

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 04-Aug-2021 - -
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 ,inter alia, to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Thursday, August 12, 2021 to consider and approve inter alia, the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2021 and 2. Payment of Interim Dividend, if any, for the financial year 2021-22. Further to our letter dated June 28, 2021 informing the closure of Trading Window of the Company from July 1, 2021 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2021, we inform you that the Trading Window will remain closed upto August 14, 2021 and shall be re-opened on August 15, 2021. Aurobindo Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12 2021 inter alia has considered and approved an Interim Dividend @ 150% i.e. Rs. 1.50 (Rupee one and paise fifty) per equity share of Re. 1/- each on the equity share capital of the Company for the Financial Year 2021-22 and the same will be paid on or before September 07 2021. The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Board of Directors at its meeting held today, August 12, 2021, has inter alia, considered and approved an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. Please refer to our letter dated August 3, 2021 wherein we have informed that the Register of Members and Share Transfer Books of the Company are being closed from August 24, 2021 to August 26, 2021 (both days inclusive) for the purpose of 34th Annual General Meeting of the Company. We hereby further inform that the aforesaid book closure dates will also be considered to determine the entitlement of the shareholders to the aforesaid interim dividend of 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the financial year 2021-22 as approved by the Board on August 12, 2021 and the same will be paid on or before September 7, 2021. (As Per BSE Announcement Dated on 8/12/2021 7:41:02 AM)
Board Meeting - 24-May-2021 - -
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a Meeting of the Board of Directors of the Company will be held on Monday, May 31, 2021 to consider, inter alia, the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021. Further to our letter dated March 29, 2021 informing the closure of Trading Window of the Company from April 1, 2021 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021, we inform you that the Trading Window will remain closed up to June 2, 2021 and shall be re-opened on June 3, 2021. The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved Audited Financial Results for the fourth quarter and year ended 31.03.2021 and other matters. The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members in the forthcoming Annual General Meeting, has approved: (a) the re-appointment of Mr. K. Nithyananda Reddy as Whole-time Director designated as Vice Chairman of the Company ; (b) the re-appointment of Mr. N. Govindarajan as Managing Director of the Company; (c) the re-appointment of Mr. Dr. M. Sivakumaran as Whole-time Director of the Company and (d) the re-appointment of Mr. M. Madan Mohan Reddy as Whole-time Director of the Company. (As Per BSE Announcement Dated on 31.05.2021)
Board Meeting - 27-Feb-2021 - -
The Board of Directors of Aurobindo Pharma Limited (the Company) at its meeting held today i.e. February 27, 2021, has approved the following: 1) Transfer of all equity shares held in Lyfius Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company. 2) Transfer of all equity shares held in Qule Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company. 3) Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare Limited, a wholly owned subsidiary of the Company.
Board Meeting - 01-Feb-2021 - -
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2021 ,inter alia, to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Wednesday, 10th February 2021 to consider and approve inter alia, the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and 2. Payment of Third Interim Dividend, if any, for the financial year 2020-21. Further to our letter dated December 29, 2020 informing the closure of Trading Window of the Company from January 1, 2021 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020, we inform you that the Trading Window will remain closed up to February 12, 2021 and shall be re-opened on February 13, 2021. The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved: 1. the Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. a Third Interim Dividend @ 150% i.e Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed February 23, 2021 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2021. The Board meeting commenced at 4.00 p.m. and concluded at 6.40 p.m. (As Per BSE Announcement Dated on 10.02.2021)
Board Meeting - 02-Nov-2020 - -
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2020 ,inter alia, to consider and approve We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Wednesday, 11th November 2020 to consider and approve inter alia, the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2020 and 2. Payment of Second Interim Dividend, if any, for the financial year 2020-21. Further to our letter dated September 28, 2020 informing the closure of Trading Window of the Company from October 1, 2020 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2020, we inform you that the Trading Window will remain closed up to November 13, 2020 and shall be re-opened on November 14, 2020. The Board of Directors of the Company at its meeting held today, November 11, 2020, has, inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. a Second Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed November 24, 2020 as the Record Date for the purpose of payment of Second Interim Dividend and the same will be paid on or before December 4, 2020. (As Per BSE Announcement Dated on 11.11.2020)
Open ZERO Brokerage Demat Account